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Abstract 51 
 52 
Eicosanoids are biologically active lipid mediators, comprising prostaglandins, leukotrienes, 53 
thromboxanes and lipoxins, involved in several pathophysiological processes relevant to 54 
asthma, allergies and allied diseases. Prostaglandins and leukotrienes are the most studied 55 
eicosanoids and established inducers of airway pathophysiology including bronchoconstriction 56 
and airway inflammation. Drugs inhibiting the synthesis of lipid mediators or their effects, such 57 
as leukotriene synthesis inhibitors, leukotriene receptors antagonists, and more recently 58 
prostaglandin D2 receptor antagonists, have been shown to modulate features of asthma and 59 
allergic diseases. This review, produced by an European Academy of Allergy and Clinical 60 
Immunology (EAACI) task force, highlights our current understanding of eicosanoid biology 61 
and its role in mediating human pathology, with a focus on new findings relevant for clinical 62 
practice, development of novel therapeutics, and future research opportunities. 63 
 64 
 65 
 66 
Abbreviation list 67 
 68 
15-oxo-ETE, 15-oxoeicosatetraenoic acid; AA, arachidonic acid; AD, atopic dermatitis; 69 
ALX/FPR2, LXA4 receptor; ATL, aspirin-triggered lipoxin; BAL, bronchoalveolar lavage; 70 
BLT1-2, LTB4 receptors 1-2; COX, cyclooxygenase, cPLA2  cytosolic phospholipase A2; 71 
CRTH2, chemoattractant receptor-homologous molecule expressed on TH2 cells; CysLT1-2, 72 
cysteinyl leukotrienes receptors 1-2; Cysteinyl-LTs, cysteinyl leukotrienes; DC, dendritic cell; 73 
DHA, docosahexaenoic acid; DHGLA, dihomo-γ-linolenic acid; DP1-2, PGD2 receptors 1-2; 74 
EBC, exhaled breath condensate; EET, epoxyeicosatrienoic acid; ELISA, enzyme-linked 75 
immunosorbent assays; EP1-4, PGE2 receptors 1-4; EPA, eicosapentaenoic acid; FLAP, 5-LO 76 
activating protein; GCs, glucocorticosteroids; GPCRs, G protein-coupled receptors; HETE, 77 
hydroxyeicosatetraenoic acid; HETrE, hydroxyeicosatrienoic acid; HpETE, 78 
hydroperoxyeicosatetraenoic acid; HPLC, high-performance liquid chromatography; ICS, 79 
inhaled corticosteroids; ILC, innate lymphoid cells; IP, PGI2 receptor; LO, LOX, lipoxygenase; 80 
LT, leukotriene; LTC4S, LTC4 synthase; LTRA, leukotriene receptor antagonists; LTSI, 81 
leukotriene synthesis inhibitors; LX, lipoxin; MC, mast cell, MS, mass spectrometry; NAEB, 82 
non-asthmatic eosinophilic bronchitis; NERD, NSAID-exacerbated respiratory disease; 83 
OXGR1, oxoglutarate receptor; P2Y12, purinergic receptor 12; PD1, protectin D1; PG, 84 
prostaglandin; PGDM, PGD2 metabolite; PPAR peroxisome proliferator-activated receptors; 85 
QoL, quality of life; sPLA2, secreted phospholipase A2; TP, TXB4 receptor; TX, thromboxane 86 
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Introduction 87 
Eicosanoids, docosanoids and related oxygenated derivatives are biologically active lipid 88 
mediators, comprising prostaglandins (PGs), leukotrienes (LTs), thromboxanes (TXs), 89 
hydroxyeicosatetraenoic acids (HETEs), lipoxins (LXs) and other pro-resolving mediators, 90 
involved in several pathophysiological processes relevant to asthma, allergies and related 91 
diseases (1). The biology of this class of mediators differs from other mediators such as 92 
cytokines or preformed proteins as they are produced within minutes upon cell activation, act 93 
locally through specific receptors and are usually quickly metabolised. PGs and LTs are the 94 
most studied eicosanoids and established players in the airway pathophysiology, producing 95 
potent and long-lasting bronchospasm, and airway inflammation mediated by interaction with 96 
receptors on a variety of structural and inflammatory cells as evidenced in several animal and 97 
human studies (2,3). Drugs inhibiting the synthesis of lipid mediators or their effects, such as 98 
LT synthesis inhibitors, leukotriene and PGD2 receptor antagonists (in clinical development) 99 
have been shown to modulate features of asthma and allergic diseases (3,4).  100 
An EAACI Task Force has been formed to provide an update on eicosanoid biology in health 101 
and disease with a focus on asthma and allergic diseases. In this report, current understanding 102 
of eicosanoids in human biology, together with new insights into their mechanisms of action 103 
and identified unmet needs for future research will be evaluated. 104 
 105 
Biosynthesis and receptors  106 
Eicosanoids, docosanoids and related oxygenated derivatives, mainly originate from 107 
arachidonic acid (AA), dihomo-γ-linolenic acid (DHGLA), eicosapentaenoic acid (EPA), and 108 
docosahexaenoic acid (DHA) (5-7). These precursor fatty acids are cleaved from membrane 109 
phospholipids by cytosolic phospholipase A2 (cPLA2 group 4A) and to a lesser extent by 110 
secreted forms of PLA2 (sPLA2) upon various stimuli (8-13). Next, free fatty acids are 111 
metabolized by three main pathways: cyclooxygenases (COXs), lipooxygenases (LOs or 112 
LOXs) or cytochrome P450, giving rise to different families of mediators (14,15) (Figure 1A). 113 
For prostanoids (PGs and TXs) biosynthesis, free fatty acids are substrates for COX-1 and 114 
COX-2 (16). Both enzymes catalyse similar two-step functionally coupled reactions: first  a 115 
cyclooxygenase reaction, forming PGG2, and immediately following a second peroxidase 116 
reaction, forming PGH2. Downstream metabolism of PGH2 depends on five different terminal 117 
synthases (PGD2, PGE2, PGF2, PGI2 and TXA2 synthases), existing in different forms, the 118 
expression of which differs depending on cell types (16) (Figure 1A). Prostanoid receptors are 119 
G protein-coupled receptors (GPCRs), activation of which results in a change (decrease or 120 
increase) in the rate of second messenger generation (cAMP or Ca2+), a change in membrane 121 
potential, and activation of specific protein kinases or arrestins (17). The biological effects of 122 
PGD2 are mediated by DP1 and DP2 (or chemoattractant receptor-homologous molecule 123 
expressed on TH2 cells (CRTH2)) and at higher concentrations by a thromboxane receptor, TP 124 
(18,19) (Figure 2A). DP1 is expressed on platelets, endothelial cells, eosinophils, basophils, T 125 
cells and different subsets of macrophages (17,20). DP2/CRTH2 is expressed on eosinophils, 126 
basophils, Th2 cells, Th2A cells, type 2 innate lymphoid cells (ILC2) and alveolar 127 
macrophages (20,21). There are four receptors for PGE2 called EP1-EP4, with contrasting 128 
functions in response to PGE2 (17,22). These receptors are expressed very broadly on many 129 
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cell types in different configurations, thus the final pro- or anti-inflammatory effect of PGE2 130 
depends on the dominance of expression of certain receptors (23) (Figure 2B). PGF2 acts on 131 
an FP receptor, mostly expressed in the uterus and in the eye (17). PGI2 (also called 132 
prostacyclin) acts on IP expressed on dendritic cells (DCs) and ILC2 (24,25). Specific 133 
metabolites of prostanoids (PGA and PGJ series) interact with the nuclear receptors: 134 
peroxisome proliferator-activated receptors (PPAR ,  and ) (26,27). They are ligand-135 
activated transcription factors which regulate expression of genes involved in immune 136 
response, lipid metabolism, adipogenesis and glucose homeostasis (26,27). 137 
  138 
Five-lipoxygenase (5-LO or 5-LOX) is the first enzyme in the LT biosynthesis (28) (Figure 139 
1A). With the help of 5-LO activating protein (FLAP), it converts AA, through intermediary 140 
hydroperoxyeicosatetraenoic acids (HpETE), into the unstable leukotriene A4 (LTA4) (29). In 141 
neutrophils and many other human cells, LTA4 is a substrate of LTA4 hydrolase (LTA4H) and 142 
is converted to LTB4, a very potent chemoattractant. In mast cells (MCs), eosinophils, 143 
monocytes (30), platelets (31) and epithelial cells, LTA4 is rapidly converted by LTC4 synthase 144 
(LTC4S) into LTC4 (Figure 1B). Following active export out of a cell, LTC4 is metabolized by 145 
a γ-glutamyl-transpeptidase to LTD4, which is further converted by a dipeptidase to LTE4 (29). 146 
There are two receptors identified for LTB4, BLT1 and BLT2, belonging to the chemokine 147 
receptor family (32). Cysteinyl leukotrienes (cysteinyl-LTs, i.e. LTC4, D4 and E4) act in human 148 
cells mainly through two recognized GPCRs: CysLT1 and CysLT2. LTD4 is a more potent 149 
agonist than LTC4 and LTE4 at the CysLT1, whereas CysLT2 is equally activated by LTD4 and 150 
LTC4 (Figure 2C). 151 
LXs, which are derivatives of AA, belong functionally to the family of pro-resolving and anti-152 
inflammatory mediators (specialized pro-resolving mediators; SPMs), together with resolvins, 153 
marensins, protectins, metabolites of DHA and EPA (33-36) (Figure 1). However, structurally 154 
and by partially utilizing the same biosynthesis enzymes (mainly 5- and 15-LOX), they are 155 
related to LTs (37). LXA4 and its epimer 15-epi-LXA4, the so-called aspirin-triggered lipoxin 156 
(ATLs), are involved in the resolution of inflammation acting on ALX/FPR2 receptor (38) 157 
(Figure 2D). 158 
Cytochrome P450 oxidases can produce various hydroxyeicosatrienoic (HETrE) and 159 
epoxyeicosatrienoic (EET) acids, performing a variety of functions within the human body (39) 160 
(Figure 1A). Detailed information about eicosanoid biosynthesis and their receptors with 161 
relation to allergy and asthma can be found in the Online Supplementary Material (link). 162 
 163 
Eicosanoids in asthma and allergy 164 
 165 
Asthma 166 
Cysteinyl-LTs. Asthma is a heterogeneous disease characterised by variable airway obstruction, 167 
airway hyperresponsiveness, chronic airway inflammation and structural changes within the 168 
airways (i.e. airway remodelling). There is ample evidence of the pivotal  role of cysteinyl-LTs 169 
in asthma pathophysiology. They induce several features of asthma including  170 
bronchoconstriction, airway inflammation, hyperresponsiveness and airway remodelling (40) 171 
(Figure 3). Cysteinyl-LTs are the most potent bronchoconstrictors in humans, a thousand times 172 
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more potent than histamine (41), inducing contraction of the airways acting through CysLT1 173 
receptor (42). Airway obstruction induced by inhaled allergen challenge in sensitised asthmatic 174 
subjects correlates with the release of cysteinyl-LTs, detected in exhaled breath condensate 175 
(EBC), bronchoalveolar lavage (BAL) and urine samples, and is effectively inhibited by 176 
pretreatment with leukotriene inhibitors or leukotriene receptor antagonists (LTRA), 177 
confirming the important role of the cysteinyl-LTs/CysLT1 pathway in allergic airway 178 
responses (43-48). Cysteinyl-LTs levels are also directly associated with asthma severity and 179 
increased in patients during asthma exacerbations (49,50). Cysteinyl-LTs have also been 180 
shown to induce mucosal oedema by increased vascular leakage, mucus hypersecretion and 181 
decreased mucociliary clearance (51-53). Recruitment and activation of many inflammatory 182 
cells critical for driving asthmatic inflammation such as eosinophils, Th2 cells, ILC2, 183 
monocytes, DCs and MCs have been shown to be significantly affected by cysteinyl-LTs, 184 
confirming that they can amplify inflammation in type 2 immunity by acting on both the innate 185 
and adaptive immune responses (2). Although cysteinyl-LTs may also play a role in airway 186 
remodelling (54,55), it is unknown whether LTRA can prevent or modify airway remodelling 187 
in patients with asthma. LTRAs have a well-established role in asthma treatment as a controller 188 
medication, showing superiority over placebo for multiple clinical outcomes such as quality of 189 
life (QoL), symptoms, lung function,  agonist use, and frequency of asthma exacerbations 190 
(56). However, LTRAs are generally less effective than inhaled corticosteroids (ICS), 191 
depending on the study population (57,58). Nevertheless, adherence to  a once-daily oral 192 
medication such as montelukast, is superior to ICS (59), while combining both drugs showed 193 
additive or synergistic benefits (60). 194 
The cysteinyl-LTs pathway plays a central role in NSAID-exacerbated respiratory disease 195 
(NERD) (61). Increased urinary LTE4 levels have been detected at baseline and during acute 196 
reaction to NSAIDs (62), while enhanced responses to inhaled LTE4 (63,64) are characteristic 197 
features of this asthmatic endotype, in which the beneficial effect of LTRA treatment further 198 
confirms a significant role of cysteinyl-LTs in pathogenesis of NERD (65). However, there are 199 
also studies showing that LTRA are equally effective in patients with NERD and patients 200 
tolerating aspirin (66).  201 
  202 
LTB4. Although increased levels of LTB4 are detected in sputum, BAL fluid and EBC from 203 
asthmatic patients (44-46), the role of LTB4 in asthma in humans is still unclear. LTB4 is strong 204 
chemoattractant for neutrophils. High numbers of those cells are usually present in the airways 205 
of asthmatic patients who suffer from exacerbations or die from asthma-related sudden death 206 
(67,68). Nevertheless, BLT receptor antagonist LY293111 failed to improve lung function or 207 
airway reactivity after allergen challenge, despite a significant reduction in the number of 208 
neutrophils in the BAL (69). It has been also hypothesized that LTB4 may have a role in 209 
neutrophilic variant asthma and COPD, which is resistant to conventional GC therapy, but the 210 
FLAP inhibitor GSK2190915 did not affect sputum neutrophils, while significantly reducing 211 
LTB4 levels (70,71). 212 
  213 
PGD2. PGD2 plays an important role in regulation of allergic inflammation in asthma. PGD2 214 
acting through DP2 (CRTH2) receptor is involved in promotion of type-2 inflammation by 215 
recruitment and activation of Th2 cells, ILC2, eosinophils, and basophils and induction of IL-216 
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4, IL-5, and IL-13 production. Increased PGD2 levels and numbers of cells expressing DP2 217 
were observed in BAL fluid from patients with severe asthma as compared to those with milder 218 
disease (72). Furthermore, upregulation of the PGD2 pathway was reported in patients with 219 
uncontrolled, severe type-2 asthma (72). Several studies of DP2 antagonists showed promising 220 
results reducing the late but not early asthmatic response following allergen challenge in atopic 221 
asthmatics and improvement in lung function, QoL, and asthma symptoms but in other trials 222 
these findings were not confirmed (3,73). There is also evidence that PGD2 may play a role in 223 
MCs mediated bronchoconstriction through activation of TP receptor (74). 224 
  225 
PGE2. PGE2 is one of the most abundant eicosanoids produced by airway epithelium and shows 226 
bronchoprotective and anti-inflammatory activity in the lungs. While PGE2 inhalation can 227 
reduce early and late phase reaction, MC activation (e.g. cysteinyl-LTs and PGD2 production) 228 
and eosinophil recruitment after allergen challenge and inhibits methacholine reactivity in 229 
asthmatics (75,76), some studies (77,78) with an oral analogue of PGE1 (PGE2 is very unstable) 230 
did not show significant improvement in pulmonary function, airway responses or symptoms 231 
suggesting a complex PGE2 interactions depending on the relative contribution of the particular 232 
receptors activated in a tissue- or cell-specific context (79). PGE2 plays a particularly important 233 
role in NERD where both decreased production of PGE2 and reduced EP2 expression were 234 
observed (80), and where a further decrease of PGE2 by COX1 inhibitors leads to MC 235 
activation and bronchoconstriction (81). Inhalation of PGE2 before aspirin challenge prevented 236 
reduction in pulmonary function and mast cell activation measured by urinary LTE4 (82). 237 
 238 
Allergic rhinitis 239 
Cysteinyl-LTs. Allergic rhinitis (AR) is defined by an IgE-mediated response in the nasal 240 
mucosa upon exposure to allergens in sensitized individuals. During the early phase of the 241 
allergic response, MCs and basophils are the primary source of eicosanoids (cysteinyl-LTs), 242 
which stimulate the production, recruitment, and activation of additional inflammatory cells, 243 
predominantly eosinophils, but also Th2 cells, ILC2, monocytes/macrophages and DCs. They 244 
are also the main source of cysteinyl-LTs during the late-phase reaction (83-85) (Figure 3). 245 
Cysteinyl-LTs produced following allergen exposure have been shown to contribute to relevant 246 
pathophysiologic processes, stimulating stimulating mucous production, increasing vascular 247 
permeability and blood flow (causing oedema), and thus, produce rhinorrhea and nasal 248 
obstruction. Increased cysteinyl-LTs levels in a nose have been found in patients with allergic 249 
rhinitis, correlating with clinical symptoms (86,87). All of the known pro-inflammatory effects 250 
of cysteinyl-LTs, including mucous hypersecretion, tissue oedema, and eosinophil recruitment, 251 
appear to be mediated through CysLT1, while the role of CysLT2 in allergic inflammation is 252 
currently unclear. The important role of CysLT1 in allergic rhinitis has been validated by 253 
numerous clinical studies with specific CysLT1 antagonists showing significant improvement 254 
in QoL and symptoms such as nasal congestion, sneezing and rhinorrhea (128). When 255 
intranasal steroids where compared with LTRAs in AR patients both treatments improved 256 
daytime and night-time symptoms with LTRAs having similar or greater effects than steroids 257 
(88-91). In some studies, additive benefits were achieved by combining an antihistamine with 258 
an LTRA or by adding LTRA to the already administered combination of intranasal steroids 259 
and antihistamine (90,92,93).  260 
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  261 
LTB4. The role of LTB4 in the pathophysiology of AR has not been well understood. Although 262 
allergen challenge induces a significant increase in numbers of neutrophils and LTB4 levels in 263 
nasal lavage fluid from patients with AR (94,95), and peripheral blood neutrophils from AR 264 
patients generate more LTB4 after calcium ionophore stimulation than those from healthy 265 
subjects, there is currently no convincing evidence for an important role of LTB4 in mediating 266 
AR symptoms (96). Interestingly, LTB4 levels in nasal lavage are not changed after topical 267 
corticosteroid treatment even with marked reduction in nasal symptoms and levels of other 268 
inflammatory mediators (97). 269 
  270 
PGD2. PGD2 levels in nasal mucosa increase after allergen challenge (98-100), and nasal 271 
obstruction and rhinorrhea are induced by intranasal administration of PGD2 (101,102). The 272 
DP2 receptor is involved in migration and activation of Th2 lymphocytes, ILC2, eosinophils, 273 
and basophils, up-regulation of adhesion molecules, and promotion of pro-inflammatory type-274 
2 cytokines (IL-4, 5, 13), whereas the DP1 receptor is associated with relaxation of smooth 275 
muscles, vasodilation, inhibition of cell migration, and apoptosis of eosinophils (18). Although 276 
several PGD2 receptors antagonists have been evaluated in treatment of patients with AR 277 
showing significant reduction of eosinophils, nasal mucosal swelling, and clinical symptoms 278 
of AR, no drugs are yet approved for clinical use.  279 
 280 
 281 
Atopic dermatitis 282 
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder characterized by 283 
eczematous lesions with lichenification of the skin. It is commonly associated with elevated 284 
levels of IgE and a family history of atopic disorders which include bronchial asthma and AR. 285 
Several observations reveal that both LTs and PGs may be crucial for the pathogenesis of AD 286 
(103) and impairment of the skin barrier (104). Increased levels of cysteinyl-LTs were detected 287 
in sera, urine and in skin extracts of AD patients which are associated with severity of the 288 
disease and exacerbations (105-107). Several studies evaluated effect of LTRA (montelukast) 289 
treatment in moderate to severe AD showing some improvements in symptoms, similar to 290 
topical steroids and oral antihistamines (108). Similarly, increased levels of LTB4 in skin 291 
lesions of patients with AD (109) as well as increased activity of LTA4H in peripheral blood 292 
cells of AD patients parallel disease severity (110). A pilot study of oral zileuton (5-LOX 293 
inhibitor) therapy in AD demonstrated promising results, supporting a functional role of LTs 294 
in AD (111). PGD2-DP2 signaling has been shown to be crucial for chemotaxis of ILC2 (112), 295 
but  a recent phase 2 clinical trial studying the effect of timapiprant (DP2 antagonist) in 296 
moderate-to-severe AD (NCT02002208) did not demonstrate any significant improvement 297 
compared with placebo.  298 
 299 
Anaphylaxis 300 
Anaphylaxis is a severe systemic hypersensitivity reaction that is rapid in onset, characterized 301 
by life-threatening breathing, and/or circulatory problems and usually associated with skin and 302 
mucosal involvement. Activation of MCs and basophils leading to release of histamine, various 303 
proteases together with de novo synthesis of cysteinyl-LTs is considered as the main 304 
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mechanism inducing anaphylactic symptoms but very limited data on immunologic 305 
mechanisms of anaphylaxis from human subjects are available because of the life-threatening 306 
nature of the disease and ethical concerns. Increased production of cysteinyl-LTs and PGD2 307 
have been reported during human anaphylaxis (113,114) and single case reports described the 308 
use of LTRA in preventive treatment of exercise induced anaphylaxis (115,116) but any in-309 
depth analysis of the role of eicosanoids in human anaphylaxis is lacking. In addition, it has 310 
been shown in in vitro and in animal studies that human and mouse mast cells produce also the 311 
omega-3 fatty acid epoxides which can promote IgE-mediated activation of mast cells and 312 
contribute to anaphylaxis (117).  313 
 314 
Food allergy 315 
Food allergy is an abnormal, sometimes life-threatening immune response that occurs 316 
reproducibly on exposure to certain foods. MC and basophil produced mediators, including 317 
leukotrienes and PGD2 are important in the effector phase of allergic response to food. Urinary 318 
tetranor-PGDM (PGD2 metabolite) has been suggested as a useful diagnostic marker of food 319 
allergy (118,119).  A recent study suggested that measurement of urinary PGDM enables 320 
objectification of positive food challenge tests helping to reduce observer bias and false-321 
positive diagnosis in food allergic patients (120). Thus, levels of specific eicosanoids might 322 
reflect disease severity of food allergy. Eicosanoids might additionally contribute to food 323 
allergy development, even if derived from parasites. Tick salivary PGE2 was suggested to 324 
contribute to α-gal-induced meat allergy via induction of antibody class switching in mature 325 
B-cells (121). NSAID use can be an important co-factor associated with food-induced 326 
anaphylaxis and while the underlying mechanisms are unknown, the modification of 327 
prostaglandin synthesis may play a role (122). Structural analogues that bind prostaglandin 328 
receptors can be secreted by the gut microbiome, however their role in food allergy has not 329 
been determined (123). Taken together, further studies are needed to define the contribution of 330 
eicosanoid metabolites to food allergy. 331 
 332 
Areas of special focus, unmet needs and future perspectives in current eicosanoid clinical 333 
and basic research 334 
 335 
Specialized pro-resolving mediators (SPM) 336 
While a debate is still evolving about the identification and characterization of their target 337 
receptors (ALX/FPR2, ChemR23/ERV1, GPR32/DRV1, GPR18/DRV2, GPR37/NPD1) (124-338 
126) SPMs are emerging as crucial signals for the resolution of tissue inflammation (36), as 339 
their levels or their signaling molecules are defective in chronic inflammatory diseases such as 340 
asthma. It suggests that the pathogenesis of this disease might be related to the defective 341 
mechanisms of the inflammation resolution (125,127). In particular, in lung tissue the cellular 342 
sources of SPMs include bronchial and alveolar epithelial cells and macrophages, all of which 343 
possess at least part of the enzymatic machinery to synthesize SPMs (109). 344 
The AA-derived lipoxins are decreased in induced sputum, BAL fluid, and exhaled breath 345 
condensates (EBC) in patients with severe asthma compared with healthy controls, and their 346 
levels inversely correlate with a worsening of airflow obstruction in severe asthma (128). In a 347 
small trial in asthmatic subjects, LXA4 inhalation significantly reduced bronchial reactivity to  348 
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LTC4 challenge (129). Similarly, also DHA-derived protectin D1 (PD1) (NPD1 when of 349 
neuronal origin) and its immediate precursor 17 hydroxy-DHA, have been identified in EBC 350 
from healthy subjects, and significantly lower concentrations were detected in EBC from 351 
patients during asthma exacerbation. PD1 treatment before aerosol challenge reduces airway 352 
hyperresponsiveness and inflammation by blocking the upregulation of IL-13, cysteinyl-LTs, 353 
and PGD2, as well as lymphocyte and eosinophils recruitment, providing evidence for 354 
endogenous PD1 as a potential counter-regulatory signal in airway inflammation (130). 355 
Intriguingly, in a small in vivo study in cystic fibrosis subjects 6 weeks of DHA 356 
supplementation caused a decrease in the concentrations of pro-inflammatory mediators 15-357 
HETE and LTB4 and a significant decrease in the 15-HETE/17OH-DHA ratio, suggesting that 358 
DHA supplementation may in part correct the imbalance in fatty acid metabolism and pointing 359 
to possible new therapeutic strategies to modulate inflammation in the lung (131). 360 
 361 
PGE2 in allergic inflammation 362 
While negative effects of  PGD2 signalling especially through its DP2 receptor on a variety of 363 
cells in the context of allergy and asthma seem to be rather clear and have led to the ongoing 364 
developments of DP2 antagonists (21,132-134), PGE2 signalling and its involvement in type 2 365 
inflammation remain incompletely understood (2,132,135). PGE2 is produced by and acts on a 366 
variety of cells in human airways, including epithelial cells, smooth muscle cells, fibroblasts, 367 
macrophages, MCs, eosinophils, T cells and ILCs. PGE2 acts in either a pro- or an anti-368 
inflammatory manner, depending on which receptors are involved (132,136). Several reports 369 
confirmed that PGE2 administered to allergic asthmatic patients before allergen challenge 370 
reduced bronchoconstriction and eosinophil infiltration, acting probably through EP2 and/or 371 
EP4-mediated mechanism on MCs, smooth muscle cells and eosinophils among others by 372 
reducing PGD2 and cysteinyl-LTs (74-76,137,138). In contrast, studies using misoprostol (a 373 
stable PGE1 analogue), did not confirm these results, but this might be related to the lower 374 
potency of misoprostol in activating cAMP-dependent pathways (77,139). Bronchoprotective 375 
and anti-eosinophilic PGE2 activity has been clearly demonstrated in patients with NERD and 376 
in patients with exercise induced bronchoconstriction (140-146). Likewise, in patients with 377 
non-asthmatic eosinophilic bronchitis (NAEB), characterized by sputum eosinophilia but 378 
without AHR, increased sputum PGE2 protects against smooth muscle proliferation (147,148) 379 
and MCs migration (149,150). In terms of allergic inflammation, some in vitro and in vivo 380 
animal studies suggest that PGE2 might drive type 2 and type 17 inflammation, especially 381 
during sensitisation phase, acting directly on DCs, naïve T cells, ILC3, IL-33-producing 382 
macrophages or MCs (151-157). In contrast, others showed that PGE2 inhibits IL-5 production 383 
by activated human T cells, suppresses expression of GATA3 and production of IL-5 and IL13 384 
by activated human ILC2, inhibits eosinophil trafficking and inhibits MC activation 385 
(74,135,158,159). Similarly, PGE2 inhibits NLRP3 inflammasome activation and mature IL-386 
1 release in human and mouse macrophages via EP4 receptor and cAMP-related pathways, 387 
when acting after the first step in NLRP3 inflammasome activation cascade (called priming) 388 
(23,160). However, PGE2 while acting before priming can also increase the production of pro- 389 
IL-1 (161). Both phenomena might have implications in some endotypes of severe asthma 390 
with significant involvement of inflammasome pathway (162-164).  In summary, effects of 391 
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PGE2 observed in vitro or in vivo in humans and animals vary depending on i) the dominant 392 
EP receptor expression, ii) timing of PGE2 stimulation, iii) PGE2 dose and iv) surrounding lipid 393 
and cytokine milieu. Further in vivo studies with the cell-specific and tissue-specific EP 394 
receptor knock-out animals, as well as studies in humans with highly selective EP1-4 analogues 395 
are needed to understand complex PGE2 biology (165,166). 396 
 397 
15-HETE and 15-oxo-eicotetraenoic acid 398 
15-hydroxyeicosatetraenoic acid (15-HETE) and 15-oxoeicosatetraenoic acid (15-oxo-ETE) 399 
are 15-lipoxygenase 1 (15-LO-1)-derived AA products. In humans, 15-LO-1 is highly 400 
expressed in eosinophils and epithelial cells, and oxidizes AA to 15-HpETE, which is reduced 401 
to 15-HETE by peroxidase. A second 15-lipoxygenase (15-LO-2) has been identified in 402 
prostate, lung, hair roots and cornea. The oxidation of 15-HETE by 15-hydroxyprostaglandin 403 
dehydrogenase (15-PGDH) generates 15-oxo-ETE (167).  Higher levels of 15-HETE were 404 
observed in the BAL fluid from patients with severe eosinophilic asthma,  compared to patients 405 
without airway eosinophilia (168). Furthermore, activated eosinophils from severe and aspirin-406 
intolerant asthmatic patients released increased levels of 15-HETE, which was not only 407 
attributed to the increased number of eosinophils but also to enhanced eosinophil function 408 
(169). Interestingly, it has also been shown that aspirin induces 15-HETE release from polyp 409 
tissue of patients with NERD, but not from aspirin-tolerant patients, without activation of 410 
eosinophils or mast cells (170). Mouse studies reported that allergen-induced airway 411 
inflammation was attenuated in 15-LO knockout mice (171,172). Lack of 15-LO is also 412 
associated with less IgE production after allergen challenge, supporting an important role of 413 
15-LO in the pathogenesis of allergen-induced inflammation within the lungs (173). However, 414 
other studies reported that 15-HETE is a PPAR agonist that might well be involved in anti-415 
inflammatory responses (174,175). In summary, pharmacologic inhibitors of 15-LO may 416 
represent an attractive therapeutic strategy in allergic airway diseases such as asthma, allergic 417 
rhinitis as well as in chronic obstructive pulmonary diseases. 418 
 419 
Novel leukotriene receptors 420 
Over the years, some additional receptors for cysteinyl-LTs have been postulated, but none of 421 
these putative receptors have yet received definitive confirmation in humans (124). In 422 
particular LTE4, the most stable of cysteinyl-LTs, has been thought to activate a distinct 423 
receptor (176), partly because both CysLT1 and CysLT2 poorly respond to it in vitro (177-179) 424 
and in vivo at least in control subjects (180), whereas asthmatics or patients with NERD seem 425 
to be selectively hyperresponsive to LTE4 (181). P2Y12, an ADP receptor expressed in human 426 
platelets, was one of the first candidates for a novel LTE4 receptor. Interestingly, some old 427 
reports postulated that cysteinyl-LTs may potentiate human platelet aggregation (182-184), 428 
while more recent data indicated that LTE4 could be a surrogate ligand for P2Y12 receptors 429 
(185-187). It has been shown that P2Y12 is required for lung pro-inflammatory actions of LTE4 430 
in mice lacking both CysLT1 and CysLT2 (186). Although some observations seem to support 431 
a cysteinyl-LTs effect on human platelets (Rovati, unpublished observations), P2Y12 activation 432 
by LTE4 has not been confirmed in recombinant models and in human platelets (188), 433 
suggesting that this elusive pharmacology might depend upon different experimental 434 
conditions that, in turn, might affect possible heterodimer formation and/or presence of biased 435 
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agonism. More recently, GPR99, another orphan GPCR with homology to the P2Y nucleotide 436 
receptor subfamily (189) and eventually named as the oxoglutarate receptor (OXGR1) (190), 437 
has also been postulated to represent the highly pursued LTE4 receptor, at least in mice 438 
(191,192). However, no independent confirmation of these data in human tissue is yet 439 
available, and transfection of GPR99 in a recombinant model failed to elicit any response to 440 
LTE4 while showing response to its recognized ligand, -ketoglutarate (Woszczek and Rovati, 441 
unpublished observations). Indeed, recently LTE4-induced airway obstruction and MC 442 
activation and subsequent release of PGs has been demonstrated to be completely montelukast-443 
sensitive and, therefore, CysLT1 dependent (193). Potent LTE4 mediated activation of CysLT1 444 
has also been confirmed in a human MC model, suggesting that LTE4 induced responses in 445 
vivo might be in fact mediated by CysLT1 rather than by a distinct LTE4 receptor (194). 446 
Another orphan GPCR, namely GPR17, phylogenetically located at an intermediate position 447 
between P2Y and Cysteinyl-LT receptors, has also been hypothesized to be activated by 448 
cysteinyl-LTs, antagonized by montelukast and to represent the third Cysteinyl-LT receptor 449 
(195). Although some observations corroborated these lipid mediators as agonists of GPR17 450 
(196-198), two distinct studies suggested GPR17 as a negative regulator of CysLT1 (199,200), 451 
while, in addition, three independent groups failed to demonstrate cysteinyl-LTs as cognate 452 
ligands of this receptor (200-202). 453 
 454 
Effects of glucocorticosteroids on eicosanoids  455 
Glucocorticosteroids (GCs) are presently the most effective drugs available for the treatment 456 
of asthma and allergic diseases (203). GCs potently regulate the expression of pro-457 
inflammatory and anti-inflammatory mediators, inhibit the recruitment and activation of 458 
inflammatory cells and inhibit permeability of blood vessel thus reducing oedema. The effects 459 
of GCs on eicosanoid synthesis and expression of eicosanoids pathway enzymes or receptors 460 
are exceedingly complex. Different outcomes can be observed, depending on the cell type and 461 
whether GCs are administered in vivo or in vitro (204). GCs can inhibit leukotriene-related 462 
inflammatory pathways by affecting recruitment and activation of cells responsible for 463 
leukotriene production (eosinophils, basophils, monocytes). GCs can also inhibit COX2 464 
leading to PGE2 decrease, and because PGE2 inhibits leukotriene synthesis, GCs may indirectly 465 
amplify leukotriene synthesis by removing this prostanoid break on leukotriene generation. It 466 
has been shown that short term (1-2 weeks) inhaled and oral GCs treatment did not affect levels 467 
of eicosanoids (especially cysteinyl-LTs) in asthmatics patients (205,206) suggesting only 468 
modest effects of GCs on eicosanoid production. This notion is further supported by findings 469 
of weak inhibitory activity of GCs on human MCs (207,208). These observations support the 470 
current view that at least one important component of allergic inflammation, the cysteinyl-LT 471 
pathway, remains insufficiently controlled by GCs treatment in many patients and may require 472 
specific targeting for better control of allergic disease (209). 473 
 474 
Single versus combination therapy  475 
Given their important role in the pathophysiology of asthma, several approaches to block the 476 
activity of lipid mediators (especially: cysteinyl-LTs, LTB4 and PGD2) have been explored in 477 
the past decades (3). To counteract the effects of leukotrienes, two types of compounds have 478 
been developed: i.e., leukotriene synthesis inhibitors (LTSI), blocking leukotrienes synthesis 479 
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at the site of 5-LO or its activating protein (FLAP), and LTRA, inhibiting effects of the 480 
respective leukotrienes (i.e., LTB4 or cysteinyl-LTs, respectively) at the site of their receptors. 481 
While LTRA, e.g. montelukast, have been shown to deplete eosinophils in blood and airway 482 
samples (210-212) showing effectiveness in (allergic, type-2) asthma, the added value of 483 
synthesis inhibitors may consist of their potential to reduce both eosinophils and neutrophils 484 
(213,214). Therefore, LTSI could theoretically be beneficial for the treatment of a broader 485 
number of disease subsets, including eosinophilic, mixed and neutrophilic asthma and COPD, 486 
which requires further investigation. Regarding anti-PGD2 treatment, so far DP2/CRTH2 487 
antagonists yielded modest protection against allergen-induced airway responses (215,216), 488 
while several phase II studies showed promising effects in patients with both allergic and non-489 
allergic type-2 asthma across all severities, improving symptoms, QoL and lung function, 490 
reducing rescue medication use, exacerbation rates and airway inflammation (133,217,218). 491 
Currently, several phase III studies in more severe asthma are ongoing. Given the expression 492 
of both CysLT1 and DP2 receptors on both Th2 and ILC2 cells (219,220), the combination of 493 
LTRA and DP2 antagonists may yield synergistic efficacy in type-2 asthma (and related 494 
disorders) and is worth investigating. More recent evidence showed potentially disease-495 
modifying effects by the DP2 antagonist fevipiprant by reducing both airway eosinophils and 496 
airway smooth muscle mass (221). 497 
 498 
Measuring eicosanoids in different biological fluids, technical issues, recommendations  499 
The concentration of bioactive eicosanoids in biological fluids is low, picomolar or within a 500 
range of picograms to nanograms per millilitre. Measurements of these compounds can be done 501 
by immunochemical methods or mass spectrometry. Currently, enzyme-linked immunosorbent 502 
assays (ELISAs) are in use, being fast and relatively inexpensive. The principle of the assay 503 
remains similar in all available ELISAs (Table 1). A standard or tracer competes with the 504 
measured eicosanoid in binding to a specific antibody. Available kits vary in sensitivity, but 505 
limits of quantification are generally around several picograms per millilitre. Frequently, 506 
antibodies used have some cross-reactivity between the measured eicosanoids and other 507 
molecules and manufacturer’s specificity tests are not inclusive, so the results need to be 508 
interpreted with caution. Mass spectrometry (MS) of eicosanoids is based on their 509 
chromatographic separation and ionization in well reproducible conditions. More robust but 510 
less sensitive is high-performance liquid chromatography (HPLC). Tandem mass spectrometry 511 
enables monitoring of characteristic fragmentation of eicosanoid molecules. A good signal-to-512 
noise ratio can be achieved in complex biological matrices, such as plasma/serum or urine. 513 
Preparation of biological samples involves extraction and chemical derivatisation. This is 514 
conversion of free chemical carboxy-, keto- or hydroxyl groups into esters, ethers or oximes. 515 
It enhances resolution of stereochemic isomers and these compounds which have overlapping 516 
retention time or molecular masses. Gas chromatography offers faster separation but 517 
preparation of samples is more laborious. The concentration of an eicosanoid is calculated from 518 
a calibration curve. It can be compensated for a variable extraction methodology by the prior 519 
addition of chemically identical deuterated internal standards, which are distinguished by mass 520 
spectrometry. The usual concentration ranges of selected eicosanoids in different clinical 521 
samples are presented in Table 1. Many eicosanoid measurements in blood serum are biased 522 
due to biosynthesis of these mediators by blood cells during clotting. Urine samples are 523 
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convenient for measurements of eicosanoids due to much higher levels than in blood plasma, 524 
saliva, bronchoalveolar lavage fluid or exhaled breath condensate. However, a rapid 525 
inactivation metabolism and accumulation of microsomal metabolic breakdown products 526 
interfere with the results, usually reflecting systemic production. Moreover, eicosanoid levels 527 
ought to be recalculated for variable urine concentration (e.g. per milligram of urinary 528 
creatinine) if no 24-hour collection is available. 529 
  530 
Conclusions and follow up 531 
Eicosanoids form a very complex network of potent inflammatory lipid mediators, involved in 532 
immune and structural cells metabolism and signalling. Although there is no doubt that 533 
imbalance within the eicosanoid system is strongly linked with the pathogenesis of asthma and 534 
allergic diseases, many unresolved aspects of eicosanoid biology such as characterisation of 535 
specific receptors and their ligands, the functional relevance of particular enzymatic pathways, 536 
and the complex nature of eicosanoid biosynthesis and metabolism, still significantly limit our 537 
understanding of this field. Eicosanoids have been already targeted for treatment in asthma and 538 
allergy and several novel therapeutics (in clinical trials) as well as a potential for combined 539 
blockades of different eicosanoid pathways are emphasising its importance. The presentation 540 
of consensus perspective on eicosanoids in this review and our identification of the main 541 
challenges, areas of current interest and unmet needs in modern eicosanoid research should 542 
provide a platform that will inform further basic and clinical research. Other topics of special 543 
importance as determined by the Task Force, including drug allergy, NERD, novel mechanisms 544 
of action of LTRAs, cross-pathway reactions, cannabinoids and systems biology approach in 545 
eicosanoid research, will be discussed in the following part II of this consensus report. 546 
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Table 1: Eicosanoids levels in biological fluids 571 
 572 
Eicosanoid BALF Induced 
sputum& 
Exhaled 
breath 
condensate 
Plasma Urine ELISA assay 
range 
Mass 
spectrometry 
lowest level of 
quantification 
PGE2 0.32 – 
0.81 
34-55 0,9 – 3.1 16 – 32 produced 
by kidneys 
2 - 500 (39 – 
2 500) 
2.9 
PGF2α 1.2 – 
8.0 
 0.42 – 1.39 < 50 produced 
by kidneys 
2 – 1 000 1.2 
PGD2 0.88 – 
3.1 
8-24 0.82 – 3.36 10-74 produced 
by kidneys 
19.5 – 2 500 2.1 
cysLTs 18,6 – 
27,2* 
11-52 1.9 – 5.9 37 - 108 only LTE4 
is present 
8.6 – 2 500 3.2 
LTE4 < 3 4-24 1.4 – 4.1 1 – 24 15 - 135 7.8 – 1 000 3.2 
LTB4 100 - 
168 
15-250 11.1 – 25.2 < 10 600 – 1 900 10.3 – 2 500 3.0 
PGEM n.a. 16-32 36.5 - 220 250 – 5 
000 
210 – 15 
720 
0.4-50 1.5 
PGDM n.a. 4-11 no data  380 - 2 250 6.4-400 1.6 
5-HETE < 0.3 250-750 3.2 – 7.6 250 - 450  160 – 10 000 0.9 
15-HETE 5.5 – 
13.8 
190-600 2.9 – 7.5 950 – 1 
660 
11 – 33 78 – 10 000 2.2 
11-dehydro-
TXB2 
0.69 – 
3.5 
2.6-8.8 8.0 – 12.9 2 - 60 1 290 – 16 
600 
9.8-10 000 0.73 
LXA4 122 – 
188* 
1.2 – 3.3 0.44 – 1.9 2 - 35 46 - 66 20 – 20 000 1.1 
 573 
Interquartile range in pg/mL except urine which is pg/mg creatinine 574 
n.a. – no data available 575 
& – induced sputum supernatant concentrations correspond to sputum plugs diluted 1:5 576 
* data available for non-severe asthmatics only 577 
References (222-227) 578 
  579 
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Figure legend 580 
 581 
Figure 1. Eicosanoid biosynthesis. a) Eicosanoids, docosanoids and related oxygenated 582 
derivatives, originate mainly from arachidonic acid (AA) and from dihomo-γ-linolenic acid 583 
(DHGLA), eicosapentaenoic (EPA), and docosahexaenoic acid (DHA). Various stimuli lead 584 
to the release of AA from the cellular membranes, which is further subjected to enzymatic 585 
oxidation by cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP450) 586 
enzymes, or non-enzymatic transformation dependent on reactive oxygen species. Intrinsic and 587 
extrinsic conditions shape the composition of the synthetized eicosanoids. b) Expression of 588 
certain biosynthesis pathway enzymes is limited to specific cell types. Intercellular transfer and 589 
metabolism of intermediate eicosanoid substrates allows for the generation of more complex 590 
eicosanoids. This process, called transcellular biosynthesis occurs in particular in inflammatory 591 
conditions, as a consequence of accumulation of multiple cell types in the affected tissue. 592 
 593 
Figure 2. Eicosanoid signaling. Eicosanoids exert their biological function via various G 594 
protein-coupled receptors (GPCRs), expressed differentially in different tissues and cell types. 595 
Depending on the tissue location, the concentration of the eicosanoid and targeted receptor, 596 
single mediator can induce strikingly different biological effects. a) Prostaglandin D2 (PGD2) 597 
signaling. PGD2 binds specifically to its two main receptors, known as PGD2 receptor 1 (DP1) 598 
and the prostaglandin D2 receptor 2 (DP2). These receptors are expressed abundantly in innate 599 
and adaptive immune cells. In addition, PGD2 can also act on the thromboxane A2 receptor 600 
(TP).  b) Prostaglandin E2 (PGE2) signaling. PGE2 binds specifically to its four main 601 
receptors, known as PGE2 receptor 1-4 (EP1-EP4). These receptors are expressed abundantly 602 
in innate and adaptive immune cells and each cell can respond to PGE2 in the opposite manner, 603 
depending on the dominant EP receptor expression, timing of PGE2 stimulation, PGE2 dose 604 
and surrounding lipid and cytokine milieu. c) Leukotriene signaling. Leukotrienes are locally 605 
potent mediators acting in auto- and paracrine way via 4 main receptors. Leukotriene B4 606 
receptor 1 (BLT1) is expressed in leukocytes and mediates chemotaxis and cell activation. 607 
BLT2 is expressed by a variety of immune cells, but its exact role in allergic inflammation 608 
remains to be elucidated. Leukotrienes C4, D4 and E4 (LTC4, LTD4, LTE4) target cysteinyl 609 
leukotriene receptors 1 and 2 (CysLT1 and CysLT2), expressed in smooth muscle cells, 610 
endothelial cells, as well as granulocytes, Th2 and type 2 innate lymphoid cells (ILC2). CysLT1 611 
mediates immune cell infiltration into tissues and cytokine production, and is further 612 
upregulated in inflammatory milieu. CysLT2 signaling results in an increase in vascular 613 
permeability in the airways. d) Lipoxin and resolvin signaling. Lipoxins and resolvins are 614 
driving the resolution of inflammation. In inflammatory conditions and during the class 615 
switching of eicosanoid production, the two main resolvin receptors become upregulated. 616 
Formyl peptide receptor 2 (FPR2), also known as ALX, is expressed on human neutrophils, 617 
eosinophils, macrophages, T cells and epithelial cells of the intestinal and the respiratory tract. 618 
The receptor binds a variety of lipid mediators, which results in a ligand-dependent activation 619 
of different phospholipases. FPR2 signaling leads to restoration of epithelial barrier function 620 
and resolution of allergic inflammation. Resolvin D1 receptor GPR32 (DRV1) is expressed by 621 
macrophages, neutrophils and T cells. Its activation results in increase in phagocytic activity 622 
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of macrophages, clearance of immune complexes and reduction in proinflammatory cytokine 623 
production.  624 
 625 
Figure 3. Eicosanoids in allergic airway inflammation. Balance between proinflammatory 626 
and pro-resolution lipid mediators is crucial in maintaining homeostasis. In physiological 627 
conditions, airway epithelium responds to damage by producing a.o. prostaglandin E2. In 628 
allergic disease however, the release of pro-resolution lipids is decreased and airway epithelial 629 
cells abundantly produce proinflammatory lipids, cytokines and chemokines. They further 630 
mediate chemotaxis of immune cells into the subepithelial compartment. Infiltrating immune 631 
cell become subsequently a source of other eicosanoids and cytokines, further driving the shift 632 
toward type-2 inflammation, degranulation of mast cells and neutrophils, production of 633 
allergen-specific IgE. Lipid mediators are the axis of the self-propelled inflammation. Due to 634 
the disturbed resolution, inflammation becomes chronic and results in distant complications 635 
such as smooth muscle cell hypertrophy and hyperplasia, epithelial barrier dysfunction, loss of 636 
plasticity, mucus overproduction and finally airway remodeling. 637 
  638 
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